07 June 2020
Visiongain has launched a new pharma report Controlled Release Drug Delivery Market Report 2020-2030: Forecasts by Release Mechanism (Activation-modulated Drug Delivery Systems (Hydrodynamic Pressure Activated, Magnetically Activated, Mechanically Activated, Osmotic Pressure Activated, Vapor Pressure Activated), Chemically Activated (Enzyme Activated, Hydrolysis Activated, pH Activated), Feedback Regulated Drug Delivery Systems, Micro Reservoir Partition Controlled Drug Delivery Systems, Polymer Based Systems), Technology (Coacervation, Implants, Micro Encapsulation, Targeted Delivery, Transdermal, Wurster Technique, Others), Application (Drug Eluting Stents, Infusion Pumps, Injectable, Metered Dose Inhalers, Oral Controlled-drug delivery Systems, Transdermal and Ocular Patches), and Geography (North America, Latin America, Europe, Asia Pacific, MEA).
The global controlled release drug delivery market is anticipated to grow at a lucrative CAGR of ~xyz% and anticipated to reach USD xyz billion by 2020. Visiongain anticipates that changing prescription pattern and growing demand from physicians for controlled release systems over the conventional drug delivery systems is projected to fuel market growth
Constantly growing R&D investment by pharmaceutical manufacturers to improve effective medication for chronic and non-communicable diseases such as cancer, diabetes, and hypertension is anticipated to fuel demand development. For example, Taris, a biomedical company-based R&D pipeline product TAR-200 (Gemcitabine) indicated for the treatment of bladder cancer, includes a controlled release drug delivery system. Additionally, the market growth is attributed to the aging population as this patient pool cannot tolerate high doses of drugs owing to severe side effects, thus fueling the demand for controlled release drug delivery systems.
The controlled release drugs improve efficacy, patient compliance, and drug effect on the body. Additionally, controlled drug delivery help in achieving long-term therapeutic effects as compared to the traditional delivery systems. As a result of these advantages, the global controlled drug delivery market is anticipated to flourish over the forecast period.
North America holds the majority of the market share and will continue to dominate in the future as a result of several research projects in the region, coupled with funding for research institutes from the government. Also, the market will continue to be driven by the existence of the target population and increased R&D investment by important business organizations. Asia Pacific region is expected to experience the highest growth in terms of CAGR over the forecast period owing to the growing pharmaceutical industry across the markets such as India and China. Additionally, unmet needs of patients and untapped nations in this region have been attracting investments by global players and this is expected to boost the controlled release drug delivery market growth over the forecast period.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations, and launching new products to strengthen their position in the global market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the controlled release drug delivery market.
The comprehensive market report features companies such as Alkermes plc, Aradigm Corporation, Capsugel, Coating Place, Inc., Corium International, Inc., Depomed, Inc., HELENA CHEMICAL, ICL, JCAM AGRI., Johnson and Johnson Services, Inc., KINGENTA, KOCH INDUSTRIES, Merck and Co.,Inc., MOSAIC COMPANY, NUFARM LTD., NUTRIEN, LTD., Orbis Biosciences, Inc., Pfizer, Inc., SCOTTSMIRACLE-GRO, YARA INTERNATIONAL ASA among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Russia, India, Japan, China, Australia, ASEAN, GCC and South Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.